AstraZeneca's drug Fasenra flops in COPD trial
LONDON (Reuters) - AstraZeneca's said its first respiratory biologic medicine Fasenra failed to meet its target in a clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: AstraZeneca | Chronic Obstructive Pulmonary | Clinical Trials | Health | Respiratory Medicine